Tissue Engineering and Its Potential to Reduce Prostate Cancer Treatment Sequelae-Narrative Review.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Regenerative strategies for post-prostatectomy incontinence: stem cells, exosomes, and the path to clinical resolution.American journal of clinical and experimental urology · 2026
   Review
2. Current Advances in the Use of Tissue Engineering for Cancer Metastasis Therapeutics.Polymers · 2024
   Review
3. GATA binding protein 5-mediated transcriptional activation of transmembrane protein 100 suppresses cell proliferation, migration and epithelial-to-mesenchymal transition in prostate cancer DU145 cells.Bioengineered · 2022
   Article
4. Prosthetics in urology: Current status and future directions.Indian journal of urology : IJU : journal of the Urological Society of India
   Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

4 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as